DEEJ(000423)
Search documents
东阿阿胶推出上市以来首次回购计划 拟1亿至2亿元回购股份注销
Zheng Quan Shi Bao Wang· 2025-12-04 14:28
Core Viewpoint - Dong'e Ejiao plans to repurchase A-shares with a total fund of between 100 million and 200 million yuan, marking the first share buyback and cancellation since its listing, aimed at enhancing investor confidence and recognizing the company's intrinsic value [1][2]. Group 1: Share Buyback Details - The repurchase price ceiling is set at 72.08 yuan per share, which is 150% of the average trading price over the previous 30 trading days [1]. - The estimated number of shares to be repurchased ranges from 1.3873 million to 2.7747 million, accounting for 0.22% to 0.43% of the current total share capital of 643,976,824 shares [1]. - The buyback period will last up to 12 months from the date of shareholder approval, with the board having the discretion to adjust the plan based on market conditions [1]. Group 2: Financial Position - As of September 30, 2025, Dong'e Ejiao's total assets are 12.749 billion yuan, with equity attributable to shareholders at 9.948 billion yuan and current assets at 9.823 billion yuan [2]. - The maximum repurchase amount of 200 million yuan represents only 1.57% of total assets, 2.01% of equity, and 2.04% of current assets, indicating a minimal impact on the company's financial health [2]. - The company asserts that the buyback will not significantly affect its daily operations, financial status, or future development [2]. Group 3: Business Performance and Strategy - Dong'e Ejiao reported a revenue of 4.766 billion yuan for the first three quarters of 2025, a year-on-year increase of 4.41%, with a net profit of 1.274 billion yuan, reflecting a growth of 10.53% [2]. - The company has maintained a high cash dividend policy, ranking first in the cash dividend payment rate among listed companies, with cumulative dividends exceeding 10 billion yuan since its listing [3]. - In 2025, Dong'e Ejiao made significant acquisitions, including a 70% stake in Ma Ji Pharmaceutical and an 80% stake in Alashan Corgoni Group, aiming to expand its product offerings in the male health supplement market [3].
12月4日增减持汇总

Xin Lang Cai Jing· 2025-12-04 14:09
| 1 | 6沃科技 | 实控人张友君的控股企业增持2.63万股公司股票 | | --- | --- | --- | | 2 | 东阿阿胶 | 拟1亿元-2亿元回购股份用于注销 | | | | 12.4上市公司盘后减持情况 | | 1 | 海珠约V | 董事、 高管拟合计减持不超0.0816%股份 | | 2 | 海科新源 | 董事、股东减持公司股份 | | 3 | ST瑞和 | 高管计划减持不超5.25万股 | | 4 | 联动科技 | 控股股东、实际控制人11月28日至12月3日减持38.2万股 | | 5 | 深科技 | 高管钟彦拟减持不超0.0014%股份 | | 6 | 德艺文创 | 股东吴体芳拟减持不超2%股份 | | 1 | 太阳电缆 | 第三大股东象屿集团及其一致行动人拟合计减持不超3%股份 | | 8 | 东望时代 | 股东新岭科技计划减持不超1.20%股份 | | g | 中自科技 | 股东银鞍岭英减持1.00%股份计划完成 | 据统计,12月4日,盘后飞沃科技、东阿阿胶披露增持情况。包括海森药业、海科新源、ST瑞和、联动 科技、深科技、德艺文创、太阳电缆、中自科技、东望时代在内的9家A股 ...
东阿阿胶:关于以集中竞价交易方式回购公司股份方案的公告
Zheng Quan Ri Bao· 2025-12-04 13:39
证券日报网讯 12月4日晚间,东阿阿胶发布公告称,公司拟以集中竞价交易方式回购股份,回购金额不 超过20,000万元(含)、不低于10,000万元(含),回购价格不超过72.08元/股,回购股份将用于注 销并减少注册资本,回购期限自股东会审议通过之日起不超过12个月,资金来源为公司自有资金或自筹 资金。 (文章来源:证券日报) ...
东阿阿胶推出上市以来首次回购注销方案 上限2亿元
Zheng Quan Ri Bao Wang· 2025-12-04 13:26
12月4日晚,老字号龙头企业东阿阿胶(000423)股份有限公司(以下简称"东阿阿胶")发布公告称, 公司拟使用自有资金1亿元至2亿元,通过二级市场回购公司股份,回购价格不超过72.08元/股(含)。 本次回购的股份将全部用于注销,以提升每股收益。结合此前披露的分红方案,2025年以来东阿阿胶累 计分红及回购注销总规模已超过18亿元,形成了"高分红+回购注销"的双重回馈组合拳。 此次股票回购计划是东阿阿胶上市以来首次实施股份回购并注销,标志着其在股东回报方式上的重要创 新。根据公告,回购股份将用于减少注册资本,此举可直接提升每股收益、净资产收益率等核心财务指 标,并通过优化资本结构为股东价值带来实质性增长。 值得关注的是,东阿阿胶自上市以来始终坚持高比例现金分红,累计分红金额已超过100亿元,其分红 比例连续多年保持在较高水平,在消费行业乃至整个A股市场中都较为突出。 众和昆仑(北京)资产管理有限公司董事长柏文喜在接受《证券日报》记者采访时表示,股票回购注销 通常出现在公司股价被低估且管理层对未来盈利增长有明确预期的场景。东阿阿胶此时推出该计划,既 回应了市场对公司价值回归的期待,也为长期投资者注入了信心。 ...
东阿阿胶独立董事孙晓波辞职
Bei Jing Shang Bao· 2025-12-04 13:13
北京商报讯(记者 王寅浩 宋雨盈)12月4日,东阿阿胶发布公告称,由于个人原因,孙晓波申请辞去公 司第十一届董事会独立董事职务,同时辞去第十一届董事会薪酬与考核委员会主任委员、提名委员会委 员、审计委员会委员等职务。辞职后,孙晓波将不再担任公司及公司控股子公司任何职务。 ...
上限2亿元,东阿阿胶出手抄底,推出史上首次回购注销
2 1 Shi Ji Jing Ji Bao Dao· 2025-12-04 13:08
Core Viewpoint - Dong'e Ejiao Co., Ltd. has announced a significant stock buyback plan of 100-200 million yuan, marking its first-ever share repurchase and cancellation, aimed at enhancing earnings per share and reflecting confidence in future growth [2][3] Group 1: Shareholder Return and Financial Performance - The company has maintained a high cash dividend policy since its listing, with cumulative dividends exceeding 10 billion yuan and a consistent 100% payout ratio, showcasing its strong cash flow and commitment to shareholder interests [2][3] - The stock buyback plan is expected to improve key financial metrics such as earnings per share and return on equity, contributing to a total shareholder return exceeding 1.8 billion yuan by 2025 through a combination of high dividends and share repurchase [3] - Dong'e Ejiao's third-quarter report indicates a stable cash flow with a net cash flow from operating activities greater than 1, supporting both dividends and buybacks, which highlights the sustainability of its shareholder returns [4] Group 2: Market Position and Industry Context - The company is experiencing a notable trend of shareholder concentration, with a slight decrease in the number of shareholders, indicating a narrowing of market divergence and a potential signal for long-term investors [4][5] - Despite the industry being in a recovery phase, Dong'e Ejiao has shown approximately 10% growth in revenue and net profit for the first three quarters, with a gross margin of 73.69%, reflecting strong operational performance [4][6] - The company is well-positioned in the herbal medicine sector, benefiting from brand strength and product barriers, with a diversified product matrix that includes core products like Ejiao blocks and compound Ejiao syrup [6][7] Group 3: Policy Environment and Future Outlook - Recent consumer stimulus policies and a more favorable environment for traditional Chinese medicine are expected to boost demand for Dong'e Ejiao's products, enhancing its growth prospects [7][8] - The easing of price pressure from centralized procurement policies is likely to benefit the company, allowing it to capture a larger market share and improve profitability [7] - Dong'e Ejiao is anticipated to leverage its first-mover advantage in the recovery of the consumer sector, positioning itself as a strong candidate for investment as market opportunities emerge [8]
东阿阿胶拟以1亿元至2亿元回购公司股份
Bei Jing Shang Bao· 2025-12-04 12:33
北京商报讯(记者 丁宁)12月4日晚间,东阿阿胶(000423)发布公告称,基于对未来发展的信心和对 公司内在价值的认可,为维护广大投资者利益、增强投资者信心,进一步提升公司价值,在考虑经营情 况和财务状况的基础上,公司拟以自有资金通过二级市场回购公司股份,拟回购金额不超过2亿元 (含),不低于1亿元(含)。本次回购股份将用于注销并减少公司注册资本。 ...
东阿阿胶拟1亿元至2亿元回购公司股份
Zhi Tong Cai Jing· 2025-12-04 12:21
东阿阿胶(000423)(000423.SZ)发布公告,公司拟以自有资金通过二级市场回购公司股份,回购股份 金额不超过2亿元(含),不低于1亿元(含),回购股份价格不超过人民币72.08元/股(含),期限自股东会审 议通过回购股份方案之日起不超过12个月。 ...
东阿阿胶(000423.SZ)拟1亿元至2亿元回购公司股份
智通财经网· 2025-12-04 12:15
智通财经APP讯,东阿阿胶(000423.SZ)发布公告,公司拟以自有资金通过二级市场回购公司股份,回购 股份金额不超过2亿元(含),不低于1亿元(含),回购股份价格不超过人民币72.08元/股(含),期限自股东 会审议通过回购股份方案之日起不超过12个月。 ...
东阿阿胶:拟1亿元~2亿元回购股份用于注销
Mei Ri Jing Ji Xin Wen· 2025-12-04 11:35
每经AI快讯,12月4日,东阿阿胶(000423)(000423.SZ)公告称,公司计划以集中竞价交易方式回购公 司股份,回购金额不超过2亿元(含),不低于1亿(含),回购价格不超过72.08元/股(含)。回购股份将用于 注销并减少公司注册资本。 ...